DOI : 10.1055/s-00000054

Pharmacopsychiatry

Issue 02 · Volume 52 · February 2019 DOI: 10.1055/s-009-42493

Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) and Deutsche Gesellschaft für Biologische Psychiatrie (DGBP)
Abstracts of the 1st Symposium of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) and Deutsche Gesellschaft für Biologische Psychiatrie (DGBP)
Seminaris Campus Hotel Berlin, Germany, 06.–08.03.2019

Editors: Manfred Gerlach, Würzburg; Jürgen Deckert, Würzburg; Sabine Herpertz, Heidelberg; Jens Wiltfang, Göttingen

P5.1
Junker, H; Kanes, S; Meltzer-Brody, S; Gunduz-Bruce, H; Sankoh, A; Li, H; Colquhoun, H; Rubinow, D; Zorumski, C; Doherty, J; Jonas, J: The gamma-aminobutyric acid type A receptor positive allosteric modulators brexanolone injection and SAGE-217 in the treatment of mood disorders: Results from recent placebo-controlled studies
P5.2
Nowacki, J; Kaczmarczyk, M; Chae, W; Abu-Tir, I; Salchow, P; Wingenfeld, K; Otte, C: Cardiovascular risk in young patients with a depressive disorder
P5.5
Murck, H; Heinrich, D; Adolf, C; Riester, A; Franke, A; Beuschlein, F; Reincke, M; Kuenzel, H: Moderators of the psychotropic effect of aldosterone in primary aldosteronism
P5.6
Hennings, J; Heel, S; Lechner, K; Uhr, M; Dose, T; Schaaf, L; Holsboer, F; Lucae, S; Fulda, S; Kloiber, S: Effect of mirtazapine on glucose metabolism and resting energy expenditure: Observations in “super-healthy” men under highly standardized conditions
P5.8
Abshir Ahmed, Y; Beitinger, P; Steiger, A: Effects of olanzapine on metabolic hormones in healthy male subjects